TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22576074
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rectal diclofenac suppository
Study: 20490573
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg (G2) or placebo (G1 and G3) administered 2 hours prior to surgery and in the PACU
Study: 20490573
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg (G3)
Study: 28560658
Drug: Pradefovir 10
Normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradefovir 10 mg
Study: 16239358
Drug: Food effect
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food effect at 30 mg
Study: 11194526
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of American ginseng (AG)
Study: 11194526
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of American ginseng (AG)
Study: 11194526
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g of American ginseng (AG)
Study: 11194526
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 g of AG)
Study: 9278463
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and Vitamin D supplementation (500 mg of calcium plus 700 IU of vitamin D3 per day)
Study: 28637449
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (E-TAU), facilitated referral to specialized mental health care
Study: 23052650
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation with antibiotics (n=17)
Study: 23052650
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation with antibiotics (n=18)
Study: 23052650
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibiotics only; n=25)
Study: 22077144
Drug: Apixaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (2.5 mg orally twice daily for 30 days)
Study: 22077144
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg subcutaneously once daily for 6 to 14 days)
Study: 2821784
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (other doses)
Study: 31240312
Drug: 240 g
Normalized name: aspirin 15.6 GM (240 grains) Oral Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 g banana + 150 mL control drink
Study: 31240312
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL control drink (Fresubin 2 kcal fiber, neutral flavor)
Study: 29231539
Drug: Basic pharmaceutical
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic pharmaceutical treatment and swallowing rehabilitation (Control group)
Study: 26697847
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg to 10 mg over 6 weeks)
Study: 23647738
Drug: Vx-001 +
Normalized name: VX-001 component TERT-572
DrugBank: TERT-572 (DB17286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vx-001 + Montanide ISA51 VG (2 mg, subcutaneously)
Study: 21200319
Drug: C-MB-P lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-MB-P lock solution (0.24 M sodium citrate, 0.15% methylene blue, 0.15% methylparaben, 0.015% propylparaben)
Study: 21200319
Drug: C-MB-P lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-MB-P lock solution
Study: 21200319
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 units of unfractionated heparin)
Study: 11021731
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg butorphanol tartrate (n = 31)
Study: 11021731
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg butorphanol tartrate (n = 29)
Study: 11021731
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg butorphanol tartrate (n = 30)
Study: 11021731
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg butorphanol tartrate (n = 30)
Study: 3518329
Drug: Phosphatidylserine (BS-PS)
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine (BS-PS) 3 X 100 mg for six weeks
Study: 30200906
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to bright white light therapy
Study: 26827289
Drug: GSK1278863 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 (10, 25, 50, or 100 mg)
Study: 26827289
Drug: GSK1278863 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 (10 or 25 mg)
Study: 17081815
Drug: GLP-2 (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-2 (1.6 mg)
Study: 17081815
Drug: GLP-2 (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-2 (3.2 mg)
Study: 11943529
Drug: Clo‐eye G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clo‐eye G (30 microg peribulbar clonidine)
Study: 11943529
Drug: CG (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG (oral saline and peribulbar saline)
Study: 8133101
Drug: Dexamethasone 0.15
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.15 mg/kg iv every 6 h for 2 days
Study: 8133101
Drug: Dexamethasone 0.15
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.15 mg/kg iv every 6 h for 4 days
Study: 2697955
Drug: Nadolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (mean dose 87 mg/day)
Study: 2697955
Drug: Propranolol (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (dose 144 mg/day)
Study: 2697955
Drug: Nadolol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (doses less than 200 mg/day)
Study: 2697955
Drug: Nadolol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (doses of 240 and 280 mg/day)
Study: 241365
Drug: Kö 1366
Normalized name: niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kö 1366 (0.0375 mg/kg)
Study: 241365
Drug: Practolol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (0.3 mg/kg)
Study: 20441243
Drug: Atorvastatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (30 mg/day for at least 8 weeks)
Study: 20441243
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no atorvastatin therapy)
Study: 17285097
Drug: Amitriptyline (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50-100 mg daily)
Study: 16830653
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (105 live bacilli/per dose) with 12 months M.D.T.‐MBR
Study: 16830653
Drug: Mw vaccine
Normalized name: polyethyloxazoline (200000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mw vaccine (1 x 108 killed bacilli as first dose and 0.5 x 108/dose in subsequent doses) with 12 months M.D.T.‐MBR
Study: 9220214
Drug: Buspirone 15
Normalized name: busPIRone 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 15 mg BID
Study: 9220214
Drug: Buspirone 10
Normalized name: busPIRone 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 10 mg TID
Study: 10356651
Drug: Buspirone 15
Normalized name: busPIRone 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 15 mg BID and TID
Study: 7605020
Drug: Low-dose isoflurane
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isoflurane (0.5 MAC)
Study: 7605020
Drug: Low-dose desflurane
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose desflurane (0.5 MAC)
Study: 7605020
Drug: High-dose propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose propofol (200 micrograms.kg‐1.min‐1)
Study: 7605020
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol (0.5 MAC)
Study: 1899823
Drug: High-nitrogen, isotonic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-nitrogen, isotonic, enteral feeding solution (Osmolite HN, pH = 6.4) (n = 7)
Study: 30634590
Drug: Daily nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily nutritional supplementation with vitamin D₃ (5000 IU) and phenylbutyrate (PBA, 2 × 500 mg)
Study: 28045352
Drug: Antidepressant prescribed
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant prescribed to older adults without MDD
Study: 28045352
Drug: Antidepressant prescribed
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant prescribed to older adults with MDD
Study: 22752690
Drug: cilengitide 240
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilengitide 240 mg/m(2) twice weekly
Study: 22752690
Drug: cilengitide 400
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilengitide 400 mg/m(2) twice weekly
Study: 22752690
Drug: cilengitide 600
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilengitide 600 mg/m(2) twice weekly
Study: 22752690
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m(2) once every 3 weeks
Study: 22333175
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once-weekly subcutaneous injection
Study: 19587338
Drug: Raxibacumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raxibacumab (40 mg/kg)
Study: 9048390
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotics (Control)
Study: 15084930
Drug: Tacrolimus (0.1+/‐0.004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.1+/‐0.004 mg/kg/d)
Study: 7785746
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2% eye drops, administered four times daily (n=153) for VKC
Study: 7785746
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2% eye drops, administered four times daily (n=146) for PAC
Study: 7785746
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2% eye drops, administered twice daily (n=677) for SAC
Study: 7785746
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 2% eye drops, administered four times daily for SAC
Study: 2204243
Drug: Bivalent Salmonella
Normalized name: Salmonella typhi Ty21a live antigen Delayed Release Oral Capsule [Vivotif]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent Salmonella typhi-Shigella sonnei vaccine, 3 doses of 10^9 organisms each
Study: 31023272
Drug: Brazilian green
Normalized name: BRAZILIAN PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazilian green propolis extract at a dose of 500 mg/day for 12 months
Study: 27891757
Drug: Alogliptin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin alone (25 mg once daily)
Study: 27891757
Drug: Alogliptin/metformin once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin/metformin once daily (500 mg once daily)
Study: 27891757
Drug: Alogliptin/metformin twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin/metformin twice daily (250 mg twice daily)
Study: 27891757
Drug: Alogliptin/metformin once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin/metformin once daily
Study: 25540059
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg once daily starting 3 days preoperatively and continuing within 5 days postoperatively
Study: 22528588
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 mg/day (600 IU/day) for 8 weeks (Group A)
Study: 22528588
Drug: Baseline values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline values (Group A before treatment)
Study: 22147126
Drug: introducer PEG-gastropexy
Approvals — FDA: no, EMA: no, PMDA: no
Description: introducer PEG-gastropexy technique without antibiotics
Study: 22147126
Drug: pull PEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pull PEG with antibiotics
Study: 17074945
Drug: Integrated psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated psychological and nicotine replacement therapy intervention (8 sessions)
Study: 15636169
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (SP) supplementation (40 g daily for 3 months)
Study: 7970122
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg preoperatively and 20 mg b.d. postoperatively for 3 months (group NL)
Study: 7970122
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg preoperatively and 20 mg b.d. postoperatively for 48 h followed by placebo for 3 months (group NS)
Study: 364631
Drug: Emepronium bromide
Normalized name: emepronium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emepronium bromide (100 mg in 100 ml saline solution)
Study: 364631
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (100 ml)
Study: 27860410
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg every 2 weeks
Study: 23464532
Drug: AZD1656 10-140
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1656 10-140 mg
Study: 23464532
Drug: AZD1656 20-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1656 20-200 mg
Study: 23464532
Drug: Glipizide 5-20
Normalized name: glipizide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 5-20 mg
Study: 23464532
Drug: Open-label AZD1656
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label AZD1656 20-200 mg
Study: 19041436
Drug: EE 30
Normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 30 mcg + CMA 2 mg (Belara)
Study: 19041436
Drug: EE 30
Normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 30 mcg + Desogestrel 0.15 mg (Marvelon)
Study: 16954556
Drug: 111In-DTPA-D-Phe1-octreotide therapy
Normalized name: DTPA
DrugBank: Pentetic acid (DB14007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 111In-DTPA-D-Phe1-octreotide therapy
Study: 16954556
Drug: Transhepatic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transhepatic administration of 111In-DTPA-D-Phe1-octreotide
Study: 7684579
Drug: HMW‐HES (high‐molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMW‐HES (high‐molecular weight hydroxyethyl starch solution)
Study: 3107331
Drug: Rectal thiopentone
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal thiopentone 30 mg X kg‐1
Study: 3107331
Drug: Methohexitone 20
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone 20 mg X kg‐1
Study: 3107331
Drug: Methohexitone 30
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone 30 mg X kg‐1
Study: 2050997
Drug: 55 s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 55 s.c. injection course of 5 M unit recombinant human alpha‐interferon (group 1, 14 patients)
Study: 2050997
Drug: Adenine‐arabinoside (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenine‐arabinoside (for 21 days) combined from the fourteenth day on with the same 55 s.c. injection schedule of interferon (group 2, 15 cases)
Study: 6407408
Drug: Mitomycin C,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin C, 20 mg/m2 I.V. direct once every 6 weeks, four courses
Study: 17631795
Drug: Manipulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulation treatment
Study: 15200444
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose hemodialysis
Study: 12759208
Drug: Conventional vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional vein harvest and storage in a crystalloid solution
Study: 12759208
Drug: Endoscopic vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic vein harvest and storage in crystalloid solution
Study: 12759208
Drug: Conventional harvest
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional harvest under continuous perfusion of the vein with 100 ml blood via the heart lung machine
Study: 9422580
Drug: General treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: General treatment with increased radiation doses
Study: 7866003
Drug: Salvia miltiorrhiza
Normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia miltiorrhiza composite injection (SMCo)
Study: 2502567
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% mupirocin ointment, applied three times a day for seven days
Study: 2502567
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% fusidic acid ointment, applied three times a day for seven days
Study: 25886378
Drug: Capecitabine (CAP)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (CAP) 825 mg/m² twice daily for 5 days per week for 5 weeks with Bevacizumab (BEV) 5 mg/kg once every 2 weeks (3 doses)
Study: 25886378
Drug: Capecitabine (CAP)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (CAP) 825 mg/m² twice daily for 5 days per week for 5 weeks without Bevacizumab (BEV)
Study: 22968823
Drug: Subconjunctival triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival triamcinolone injection (20 mg, 1-3 injections at 3-week intervals)
Study: 21480416
Drug: Astaxanthin 5
Normalized name: astaxanthin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin 5 mg once daily for 3 weeks
Study: 21480416
Drug: Astaxanthin 20
Normalized name: Astaxanthin 200mcg, Krill oil 1,000mg, Phospholipid 400mg Oral capsule, liquid filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin 20 mg once daily for 3 weeks
Study: 15031516
Drug: Okavax (varicella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Okavax (varicella vaccine)
Study: 15031516
Drug: Trimovax (MMR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimovax (MMR vaccine)
Study: 15031516
Drug: Okavax and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Okavax and Trimovax administered concomitantly
Study: 15031516
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of Okavax and Trimovax
Study: 7794307
Drug: Fluconazole 3
Normalized name: Fluconazole 3 mg/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 3 mg/kg once daily
Study: 9462438
Drug: Nystatin 50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin 50,000 units/kg/day in four divided doses
Study: 7935145
Drug: Barrier creams
Normalized name: Valiant Barrier
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier creams
Study: 7935145
Drug: Hydrocarbon cream
Normalized name: PARAFFIN HYDROCARBONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocarbon cream
Study: 3127585
Drug: Auranofin (AF)
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin (AF) treatment
Study: 28689511
Drug: Group PM+
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group PM+ intervention (five weekly sessions of 2 hours duration delivered by local non-specialist females under supervision)
Study: 29871263
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray combined with oral montelukast
Study: 29871263
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray alone
Study: 23802989
Drug: Problem Solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Solving Therapy in addition to the standard rehabilitation program
Study: 17117294
Drug: Adequate calcium
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate calcium intake (1000-1500 mg/d) from dairy foods
Study: 1430299
Drug: Intravenous cefprozil
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefprozil 250 mg
Study: 1430299
Drug: Intravenous cefprozil
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefprozil 500 mg
Study: 1430299
Drug: Intravenous cefprozil
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cefprozil 1000 mg
Study: 1430299
Drug: Oral cefprozil
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefprozil 500 mg